Last reviewed 2026-05-27 · How we verify

NORGESTOMET

FDA-approved active Small molecule ✓ Verified May 2026 Quality 10/100

NORGESTOMET is a drug. It is currently FDA-approved.

Norgestomet is a small molecule. It has multiple synonyms, including Norgestomet, Norgestomet, Norgestomet, and SC-21009.

At a glance

Generic name	NORGESTOMET
Target	Progesterone receptor
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

NORGESTOMET CI brief — competitive landscape report
NORGESTOMET updates RSS · CI watch RSS

Frequently asked questions about NORGESTOMET

What is NORGESTOMET?

NORGESTOMET is a Small molecule drug.

What development phase is NORGESTOMET in?

NORGESTOMET is FDA-approved (marketed).

What does NORGESTOMET target?

NORGESTOMET targets Progesterone receptor.

Target: All drugs targeting Progesterone receptor
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing